ABEO - NASDAQ

Abeona Therapeutics Inc.

ABEO·NASDAQ

$5.89

+3.6%

HealthcareBiotechnology

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$335.99M

EPS1.3400

P/E Ratio4.40

Earnings Date08/13/2026

219.57M

Assets

102%

3Y+242.0%

5Y+45.0%

10Y+98.0%

60.35M

Total Liabilities

-7%

3Y+61.0%

5Y+24.0%

10Y+405.0%

159.22M

Total Equity

262%

3Y+495.0%

5Y+55.0%

10Y+61.0%

Abeona Therapeutics Inc. Funding & Solvency Profile

ABEO · NASDAQ

Current Assets

Cash & Cash Equivalents78.44M

Net Receivables6.71M

Inventory5.49M

Other Current Assets1.29M

Total Current Assets205 M

Non-Current Assets

Property, Plant & Equipment13.88M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets781.00K

Total Non-Current Assets15 M

Total Assets

219.57M

Financial Health Analysis

Current Ratio

6.93x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.38x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

175 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

93% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Abeona Therapeutics Inc. Balance Sheet

ABEO • NASDAQ

Abeona Therapeutics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	78.4M	23.4M	14.5M	14.2M	32.9M	12.6M	129.3M	18.8M	137.8M	69.1M	40.1M	11.5M	424K	396K	2.5M	7M	607K	2.7M	6.9M	1.2M
Short-Term Investments	113M	74.4M	37.8M	37.9M	12.1M	82.4M	0.0	66.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8M	3.2M
Cash & Short-Term Investments	191.4M	97.7M	52.2M	52.1M	45M	95M	129.3M	85M	137.8M	69.1M	40.1M	11.5M	424K	396K	2.5M	7M	607K	2.7M	6.9M	4.4M
Net Receivables	6.7M	1.7M	2.4M	188K	3M	0.0	0.0	81K	107K	124K	115K	35K	74K	840K	333K	1M	36K	147K	966K	359K
Accounts Receivables	6.1M	0.0	0.0	0.0	3M	0.0	0.0	81K	107K	124K	115K	35K	74K	840K	333K	1M	36K	147K	966K	359K
Other Receivables	568K	1.7M	2.4M	188K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	5.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	194K	151K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	729K	0.0	7.4M	2.7M	3.1M	3.8M	2.7M	155K	315K	0.0	77K	251K	39K	70K	42K	175K	410K	283K
Other Current Assets	1.3M	1.5M	338K	762K	891K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	330K	0.0	0.0	0.0	0.0	0.0
Total Current Assets	204.9M	100.9M	55.7M	53.1M	56.3M	97.7M	132.4M	88.9M	140.6M	69.4M	40.6M	11.6M	575K	1.7M	3.3M	8.1M	685K	3M	8.3M	5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	13.9M	8M	8M	11.1M	21.7M	18.4M	21.2M	9.4M	1.4M	721K	350K	4K	6K	7K	51K	32K	50K	95K	130K	212K
Goodwill	0.0	0.0	0.0	0.0	0.0	32.5M	32.5M	32.5M	32.5M	32.5M	32.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	1.4M	1.5M	36.2M	43M	4M	8.4M	6.6M	5M	0.0	0.0	362K	574K	787K	999K	710K	903K
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	1.4M	34M	68.6M	75.5M	36.4M	40.9M	39.1M	5M	0.0	0.0	362K	574K	787K	999K	710K	903K
Other Non-Current Assets	781K	96K	277K	43K	168K	1.1M	1.1M	597K	357K	66K	62K	32K	32K	42K	59K	44K	61K	78K	12K	280K
Total Non-Current Assets	14.7M	8.1M	8.3M	11.1M	23.3M	53.5M	91M	85.5M	38.2M	41.6M	39.5M	5M	38K	49K	472K	650K	898K	1.2M	852K	1.4M
Total Assets	219.6M	108.9M	64M	64.2M	79.6M	151.2M	223.4M	174.4M	178.8M	111.1M	80.1M	16.6M	613K	1.7M	3.8M	8.8M	1.6M	4.2M	9.1M	6.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	8M	3.4M	6.4M	1.8M	8.9M	36.2M	31.2M	16.1M	1.9M	7.7M	875K	1.9M	7.5M	5.5M	8.2M	7.4M	6.9M	5.2M	1.8M	1.2M
Accounts Payable	7.9M	3.4M	1.9M	1.8M	4.3M	4.7M	3.8M	6.1M	1.9M	3.7M	875K	1.9M	863K	2M	1.7M	3M	4.1M	3.3M	1.5M	1.2M
Other Payables	126K	0.0	4.6M	0.0	4.6M	31.5M	27.4M	10M	0.0	4M	0.0	0.0	6.7M	3.5M	6.5M	4.4M	2.8M	1.9M	260K	0.0
Accrued Expenses	0.0	1.9M	2.3M	1.4M	3.8M	3.4M	5.5M	3.9M	512K	0.0	0.0	0.0	857K	857K	955K	983K	1.4M	1.4M	160K	581K
Short Term Debt	13.1M	5.9M	0.0	0.0	0.0	330K	0.0	10M	0.0	0.0	0.0	400K	0.0	0.0	2.8M	5.5M	0.0	825K	64K	8.8M
Capital Lease Obligations (Current)	0.0	823K	998K	1.8M	1.8M	1.7M	1.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	296K	296K	296K	296K	3.2M	602K	602K	602K	578K	247K	285K	347K	347K	164K	68K	173K
Other Current Liabilities	8.5M	4.5M	3.7M	2.8M	1.8M	0.0	0.0	-10M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Liabilities	29.6M	16.6M	13.4M	7.8M	16.6M	42M	38.7M	20.4M	5.6M	8.3M	1.5M	2.9M	9M	6.6M	12.2M	14.3M	8.6M	7.6M	2.1M	10.8M
NON-CURRENT LIABILITIES
Long Term Debt	7.8M	13M	0.0	0.0	0.0	1.4M	0.0	20M	0.0	0.0	4M	4M	0.0	0.0	0.0	0.0	5.5M	5.5M	5.5M	5.5M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	3.7M	4.3M	4.9M	5.2M	2.7M	3.3M	4.4M	4.7M	2.2M	910K	0.0
Other Non-Current Liabilities	18.9M	32M	31.4M	23.8M	13M	0.0	0.0	0.0	0.0	0.0	2.6M	0.0	1.2M	9.5M	5.9M	10.9M	9.7M	0.0	0.0	0.0
Total Non-Current Liabilities	30.8M	48.3M	35.8M	29.7M	20.6M	6.7M	6.3M	20M	3.1M	3.7M	10.9M	8.9M	6.4M	12.2M	9.2M	15.3M	19.9M	7.7M	6.4M	5.5M
Capital Lease Obligations	4.1M	4.1M	5.4M	7.6M	9.4M	7M	8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	60.4M	64.9M	49.2M	37.5M	37.2M	48.6M	45M	40.4M	8.7M	12M	12.3M	11.8M	15.4M	18.8M	21.4M	29.6M	28.6M	15.4M	8.5M	16.3M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-4K	-4K	-4K	-4K	-4K	-4K	-4K	-4K
Common Stock	550K	457K	265K	177K	1.5M	961K	836K	479K	469K	403K	328K	200K	6K	247K	239K	191K	132K	95K	36K	35K
Additional Paid-In Capital	900.6M	856.8M	764.2M	722M	696.6M	672.3M	664.1M	543.8M	529.4M	431.2M	378M	300.7M	251.6M	250.7M	237.6M	230.2M	215.7M	225.8M	116M	68.8M
Retained Earnings	-742.1M	-813.3M	-749.5M	-695.3M	-655.6M	-570.7M	-486.5M	-410.2M	-359.8M	-332.5M	-310.6M	-296.1M	-266.4M	-268M	-255.4M	-251.1M	-241.8M	-236M	-114.3M	-77.7M
Accumulated Other Comprehensive Income/Loss	138K	8K	-66K	-129K	-27K	-10K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1M	-1M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1M	-1M	0.0	0.0
Total Stockholders' Equity	159.2M	44M	14.8M	26.8M	42.4M	102.6M	178.4M	134M	170.1M	99.1M	67.7M	4.8M	-14.8M	-17.1M	-17.6M	-20.8M	-27M	-11.2M	681K	-9.9M
Total Equity	159.2M	44M	14.8M	26.8M	42.4M	102.6M	178.4M	134M	170.1M	99.1M	67.7M	4.8M	-14.8M	-17.1M	-17.6M	-20.8M	-27M	-11.2M	681K	-9.9M
SUMMARY
Total Liabilities & Equity	219.6M	108.9M	64M	64.2M	79.6M	151.2M	223.4M	174.4M	178.8M	111.1M	80.1M	16.6M	613K	1.7M	3.8M	8.8M	1.6M	4.2M	9.1M	6.4M
Total Investments	113M	74.4M	37.8M	37.9M	12.1M	82.4M	0.0	66.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8M	3.2M
Total Debt	25M	23M	5.4M	7.6M	9.4M	8.7M	8M	30M	0.0	0.0	4M	4.4M	0.0	0.0	2.8M	5.5M	5.5M	6.3M	5.6M	14.3M
Net Debt	-53.5M	-309K	-9.1M	-6.6M	-23.6M	-3.9M	-121.3M	11.3M	-137.8M	-69.1M	-36.1M	-7.1M	-424K	-396K	290K	-1.5M	4.9M	3.6M	-1.4M	13.1M
Shares Outstanding	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398	51,277,398

SEC Filings

ABEO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 04, 2026	June 03, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 16, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 17, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 17, 2026	March 17, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 494 filings

Related Guides

Blog Categories

Continue your ABEO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.